Scancell Holdings PLC (GB:SCLP)
LSE:SCLP
Want to see GB:SCLP full AI Analyst Report?
SCLP Stock Chart & Stats
9.75 p
0.40 p(4.06%)
At close: 4:00 PM EST
9.75 p
0.40 p(4.06%)
Day’s Range― - ―
52-Week Range7.86 p - 14.00 p
Previous CloseN/A
Volume797.06K
Average Volume (3M)1.20M
Market Cap
£132.32M
Enterprise Value139.93M
Total Cash (Recent Filing)£8.57M
Total Debt (Recent Filing)£16.18M
Price to Earnings (P/E)―
Beta0.24
Next Earnings
Oct 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,037,781,400
10 Day Avg. Volume991,653
30 Day Avg. Volume1,200,950
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)-27.20
Price to Sales (P/S)22.14
P/FCF Ratio-17.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£833.33K
Bulls Say, Bears Say
Bulls Say
Compelling Phase II Efficacy And Biomarker EnrichmentA strong 74% PFS signal from Phase II, plus an identified biomarker to enrich responders, materially raises the probability that the randomized Phase III will show a clinically meaningful effect. Biomarker enrichment and adaptive design can lower development risk and improve partner interest over the multi-year program.
FDA IND Clearance And Surrogate Primary EndpointRegulatory acceptance of the IND and a surrogate primary endpoint provides a structurally faster, de-risked regulatory path (accelerated approval potential). That regulatory traction strengthens long-term partnerability and strategic options, and shortens the timeline to potential market access if confirmatory data align.
Scalable Manufacturing And Partnered Upside (PharmaJet, Genmab)Having validated scalable manufacturing and a commercial delivery partner reduces commercialization execution risk. The Genmab licensing pathway and potential $630m milestones create a durable non-dilutive financing channel and commercial validation pathway, improving long-term commercialization and funding optionality.
Bears Say
Negative Shareholder Equity And Elevated DebtPersistent negative equity and material debt relative to modest assets constrain financial flexibility and raise solvency optics. Over a multi‑year development program this weakens the company's ability to self-fund large trials, increases refinancing risk, and can impair bargaining power in partnership negotiations.
Short Cash Runway Necessitating Near-term FundingWith runway only into H2 2026, management must secure partnerships, milestone receipts, or financing before starting a costly registrational Phase III. That creates a persistent dilution and execution risk over the next 12–18 months and can force suboptimal terms or delays if non-dilutive alternatives don't materialize.
Long Blinded Phase III Timeline To Registrational ReadoutA blinded, global Phase III with a target readout in H2 2029 prolongs time to definitive commercial evidence and revenue. This extends dependence on external funding, increases the period of binary clinical risk, and delays value realization for investors and potential licensors over multiple years.
Scancell Holdings News
SCLP FAQ
What was Scancell Holdings PLC’s price range in the past 12 months?
Scancell Holdings PLC lowest share price was 7.86 p and its highest was 14.00 p in the past 12 months.
What is Scancell Holdings PLC’s market cap?
Scancell Holdings PLC’s market cap is £132.32M.
When is Scancell Holdings PLC’s upcoming earnings report date?
Scancell Holdings PLC’s upcoming earnings report date is Oct 23, 2026 which is in 179 days.
How were Scancell Holdings PLC’s earnings last quarter?
Scancell Holdings PLC released its earnings results on Jan 29, 2026. The company reported -0.006 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.006 p.
Is Scancell Holdings PLC overvalued?
According to Wall Street analysts Scancell Holdings PLC’s price is currently Overvalued.
Does Scancell Holdings PLC pay dividends?
Scancell Holdings PLC does not currently pay dividends.
What is Scancell Holdings PLC’s EPS estimate?
Scancell Holdings PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Scancell Holdings PLC have?
Scancell Holdings PLC has 1,037,781,400 shares outstanding.
What happened to Scancell Holdings PLC’s price movement after its last earnings report?
Scancell Holdings PLC reported an EPS of -0.006 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.804%.
Which hedge fund is a major shareholder of Scancell Holdings PLC?
Currently, no hedge funds are holding shares in GB:SCLP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Scancell Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-29.25%
12-Months-Change
Fundamentals
Return on Equity
90.29%
Trailing 12-Months
Asset Growth
-7.40%
Trailing 12-Months
Company Description
Scancell Holdings PLC
Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel vaccines and antibody medicines to treat unmet needs in cancer and infectious diseases. The company's product candidates include SCIB1, which is in phase II clinical trial for the treatment of metastatic melanoma; SCIB2 for the treatment of non-small cell lung cancer; and Modi-1 that is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2, which targets homocitrullinated cancer antigens. In addition, the company develops SCOV1 and SCOV2 COVIDITY, a prophylactic DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.
Technical Analysis
Sareum Holdings
―
4basebio UK Societas
―
Poolbeg Pharma Ltd.
―
Arecor Therapeutics PLC
―
Ondine Biomedical, Inc.
―
Options Prices
Currently, No data available
---